Latest Conference Articles

September 15th 2019, 12:22am

Society of Hematologic Oncology Annual Meeting (SOHO)

Laura C. Michaelis, MD, discusses the currently approved JAK inhibitors and the future landscape for myelofibrosis, as well as treatment considerations for graft-versus-host disease.

September 15th 2019, 12:16am

Society of Hematologic Oncology Annual Meeting (SOHO)

Early results from a prospective postmarketing assessment showed that tisagenlecleucel induced responses similar to those seen in pivotal trials for children and adolescents with B-cell acute lymphoblastic leukemia and adults with diffuse large B-cell lymphoma.

September 14th 2019, 10:54pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Basem William, MD, MRCP, FACP, discusses the preliminary results of the phase II trial of brentuximab vedotin and lenalidomide in relapsed/refractory cutaneous and peripheral T-cell lymphomas.

September 14th 2019, 8:53pm

International Myeloma Society Annual Meeting

A quadruplet regimen combining the anti-CD38 monoclonal antibody isatuximab with carfilzomib, lenalidomide, and dexamethasone was safe and had a 100% response rate among 10 patients enrolled in the safety run-in cohort of the phase II, multicenter GMMG-CONCEPT trial.

September 14th 2019, 7:49pm

International Myeloma Society Annual Meeting

Habte A. Yimer, MD, of Texas Oncology, discusses a real-world study evaluating the long-term use of proteasome inhibition in patients with multiple myeloma, and transitioning from bortezomib (Velcade) to ixazomib (Ninlaro).

September 14th 2019, 7:40pm

International Myeloma Society Annual Meeting

Katja Weisel, MD, myeloma specialist at the University of Tübingen, discusses an analysis of the INSIGHT MM study evaluating fixed-duration versus continuous therapy for patients with multiple myeloma.

September 14th 2019, 6:57pm

International Myeloma Society Annual Meeting

Pieter Sonneveld, MD, PhD, discusses the significance of the subgroup analysis of the phase III CASSIOPEIA trial evaluating the regimen of daratumumab, bortezomib, thalidomide, and dexamethasone in patients with high-risk multiple myeloma.

September 14th 2019, 5:05pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Jason Westin, MD, discusses patient responses with relapsed/refractory diffuse large B-cell lymphoma in the JULIET trial who were treated with tisagenlecleucel.

September 14th 2019, 2:49am

Society of Hematologic Oncology Annual Meeting (SOHO)

Ching-Hon Pui, MD, discusses the use of CAR T-cell therapy in patients with relapsed/refractory acute lymphocytic leukemia.

September 14th 2019, 12:15am

Society of Hematologic Oncology Annual Meeting (SOHO)

Tisagenlecleucel maintained strong rates of response and duration of response in adults with relapsed/refractory diffuse large B-cell lymphoma, according to the latest findings from the phase II JULIET study presented at the 2019 SOHO Annual Meeting.

September 13th 2019, 11:14pm

Society of Hematologic Oncology Annual Meeting (SOHO)

John F. DiPersio, MD, PhD, discusses the challenges in research surrounding targeted cellular therapies for acute myeloid leukemia

September 13th 2019, 9:13pm

Society of Hematologic Oncology Annual Meeting (SOHO)

The use of checkpoint inhibitors prior to haploidentical stem cell transplantation improved progression-free survival and reduced the risk for relapse for patients with relapsed or refractory Hodgkin lymphoma, according to results from a retrospective study presented at the 2019 SOHO Annual Meeting.

September 13th 2019, 8:21pm

Society of Hematologic Oncology Annual Meeting (SOHO)

David G. Maloney, MD, PhD, discusses the initiative to use the Center for International Blood and Marrow Transplant Research Cellular Therapy Registry to report real world experience of tisagenlecleucel CAR T cells targeting CD19 in patients with acute lymphoblastic leukemia.

September 13th 2019, 5:23pm

IASLC World Conference on Lung Cancer

Liposomal irinotecan achieved disease control in almost half of patients as a second-line treatment for small cell lung cancer, according to findings from Part 1 of the phase II/III RESILIENT trial presented at the 2019 World Conference on Lung Cancer.

September 13th 2019, 2:46am

Society of Hematologic Oncology Annual Meeting (SOHO)

Ruben Mesa, MD, discusses the JAKARTA and JAKARTA-2 studies and the implications their data have on the field of myelofibrosis.

September 13th 2019, 2:32am

Society of Hematologic Oncology Annual Meeting (SOHO)

Laura C. Michaelis, MD, discusses the integration of fedratinib into the treatment sequence of myelofibrosis.

September 13th 2019, 2:26am

Society of Hematologic Oncology Annual Meeting (SOHO)

Partow Kebriaei, MD, discusses the eligibility criteria necessary for patients with acute lymphocytic leukemia to undergo stem cell transplantation.

September 13th 2019, 1:57am

Society of Hematologic Oncology Annual Meeting (SOHO)

Novel strategies are needed to enhance the efficacy of CAR T-cell therapies in patients with acute lymphoblastic leukemia, including new constructs that target more than 1 antigen.

September 12th 2019, 8:54pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Reducing or interrupting duvelisib treatment does not increase toxicity or reduce outcomes with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Furthermore, treatment with the PI3K inhibitor led to a superior median progression-free survival compared with ofatumumab while producing rapid and durable responses in heavily pretreated patients.

September 11th 2019, 1:56am

IASLC World Conference on Lung Cancer

Rosario Garcia Campelo, MD, medical oncologist, University Hospital Caruna, talks about a randomized trial assessing health-related quality of life in patients with ALK-positive non–small cell lung cancer patients who were treated with brigatinib versus crizotinib.